Comparative Pharmacology
Head-to-head clinical analysis: ARRANON versus DTIC DOME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARRANON versus DTIC DOME.
ARRANON vs DTIC-DOME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Purine nucleoside analog; after intracellular phosphorylation to ara-GTP, it incorporates into DNA, inhibits DNA synthesis, and induces apoptosis in T-cell progenitors.
Dacarbazine is an alkylating agent that forms methyltriazenoimidazole carboxamide, causing cross-linking of DNA and inhibition of DNA, RNA, and protein synthesis.
2600 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
DTIC 250 mg/m2 IV daily for 5 days every 21-28 days, or 850-1000 mg/m2 IV as a single dose every 21-28 days.
None Documented
None Documented
Terminal elimination half-life of nelarabine is approximately 30 minutes; the active metabolite ara-G has a terminal half-life of approximately 20-24 hours. Clinically, this supports daily dosing in cycles.
Terminal elimination half-life is approximately 5 hours (range 4-7 hours) for parent drug; metabolites exhibit longer half-life (up to 8-12 hours). Clinical context: requires multiple dosing cycles due to short half-life.
Nelarabine is extensively metabolized to ara-G; elimination is primarily renal: ~27% as parent drug and 30-50% as ara-G in urine. Fecal excretion accounts for <5% of administered dose.
Renal (40-60% as unchanged drug and metabolites, primarily 5-aminoimidazole-4-carboxamide); biliary/fecal (minimal, <10%)
Category C
Category C
Antineoplastic
Antineoplastic